It expands on the reasons for relapse after CAR-T therapy (here). Not sure that it validates the benefits of allogeneic vs autologous as claimed in the post (and also by Baker) but it does show that cancer cells are highly adaptable and can evolve very quickly to threats like CAR-T therapy.
"40-60% of complete remission patients experience relapse."
"Relevant optimization and breakthroughs to promote antigen recognition, enhance CAR-T cell function, and develop combinational treatment strategies provide insights for better clinical efficacy."
Arovella's work on costimulatory domains, identification of alternative antigen treatments, combinational treatments (onCARlytics JV) and use of IL12 to increase CAR-T cells in circulation, shows this company is among those at the leading edge of this science.
A positive result in the pilot mouse study with onCARlytics will be the next pivot point for mine.
ALA Price at posting:
14.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)